Prof. Abraham Nudelman
Medicinal & Organic Chemistry Leading Advisor
Prof. Abraham Nudelman is a Professor of Cemistry at the Bar-Ilan University and chaired its Chemistry Department from 1993 to 1996. He also headed the Marcus Center for Medicinal Chemistry at Bar Ilan University form 1998 to 2009. Prof. Nudelman has been an Invited Lecturer of Medicinal Chemistry at The Weizmann Institute of Science since 1981 and was a visiting Professor in Johns Hopkins University, Baltimore, MD, USA and in UCLA, CA, USA.
Prof. Nudelman's main interest is in Medicinal and Organic Chemistry. He was a researcher at Medicinal Chemistry Division of Wyeth Laboratories for 6 years and a Visiting Scientist at E. I. Du Pont de Nemours Central Research Division for 5 years.
Prof. Nudelman is the author of over 120 publications and the inventor of over 75 patents.
Senior Strategic Advisor
Yelena has over 20 years of senior management experience in pharmaceutical, biotech and IT companies. She was formerly Vice President & General Manager of Rosetta BioSoftware (Business Unit of Merck & Co acquired by Microsoft in 2009) and is currently Managing Director at iTechomics Solutions, providing consulting services to the life science industry with the aim of bringing to market enabling technologies from the convergence of life sciences and information sciences.
Business Development Consultant Europe
Daniel is pharmacist by training having over 30 years of experience in the pharmaceutical industry working in various positions for Medium and Big Pharmaceutical companies: Aventis, Bristol Myers Squibb, Schering AG and Bayer AG. From 1992 to 2007 Daniel was the CEO of the French subsidiary of Schering AG. Following the acquisition of Schering by Bayer, Daniel spent two years managing the integration between the companies in France. In 2009 Daniel founded his own company, DBS Consulting, with a goal to assist Healthcare Industry players to improve their economic performances
Lance Stewart - Ph.D. MBA.
Lance is a life sciences entrepreneur with over 15 years of experience in pre-clinical drug discovery. He currently serves as the Chair of the Advisory Board for Emerald BioStructures, and advises a number of early stage life science technology companies. Lance also serves as a Co-principal Investigator for the Seattle Structural Genomics Center for Infectious Disease (SSGCID). Dr. Stewart co-founded Emerald BioStructures in 1998 and led the growth of Emerald as a business unit within two publicly traded companies (MCLS and DCGN) and the successful spin out from deCODE genetics in November 2009. Lance holds a PhD in Biochemistry and Virology from Cornell University and held a Research Assistant Professor position in the University of Washington, he also holds an Executive MBA from the University of Washington.